SCARB2 variants and glucocerebrosidase activity in Parkinson's disease
- PMID: 27110593
- PMCID: PMC4838276
- DOI: 10.1038/npjparkd.2016.4
SCARB2 variants and glucocerebrosidase activity in Parkinson's disease
Abstract
Mutations in glucocerebrosidase (GBA) are a common risk factor for Parkinson's disease (PD). The scavenger receptor class B member 2 (SCARB2) gene encodes a receptor responsible for the transport of glucocerebrosidase (GCase) to the lysosome. Two common SNPs in linkage disequilibrium with SCARB2, rs6812193 and rs6825004, have been associated with PD and Lewy Body Disease in genome wide association studies. Whether these SNPs are associated with altered glucocerebrosidase enzymatic activity is unknown. Our objective was to determine whether SCARB2 SNPs are associated with PD and with reduced GCase activity. The GBA gene was fully sequenced, and the LRRK2 G2019S and SCARB2 rs6812193 and rs6825004 SNPs were genotyped in 548 PD patients and 272 controls. GCase activity in dried blood spots was measured by tandem mass spectrometry. We tested the association between SCARB2 genotypes and PD risk in regression models adjusted for gender, age, and LRRK2 G2019S and GBA mutation status. We compared GCase activity between participants with different genotypes at rs6812193 and rs6825004. Genotype at rs6812193 was associated with PD status. PD cases were less likely to carry the T allele than the C allele (OR=0.71; p=0.004), but GCase enzymatic activity was similar across rs6812193 genotypes (C/C: 11.88 μmol/l/h; C/T: 11.80 μmol/l/h; T/T: 12.02 μmol/l/h; p=0.867). Genotype at rs6825004 was not associated with either PD status or GCase activity. In conclusion, our results support an association between SCARB2 genotype at rs6812193 and PD, but suggest that the increased risk is not mediated by GCase activity.
Conflict of interest statement
R.N.A. is supported by the Parkinson’s Disease Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040, formerly the National Center for Research Resources, Grant Number UL1 RR024156), the Smart Foundation and the Brookdale Foundation. He received consultation fees from Genzyme/Sanofi and Prophase. Ms P.W. and Drs P.O. and X.K.Z. are employees of Genzyme/Sanofi. Dr S.F. reports Consulting and Advisory Board Membership with honoraria: Merz Pharma, Genervon Biotechnology; PixarBio; Lundbeck Pharma. Grants/Research Support: 69Genervon Biotechnology. U.K. reports research grants from NIH, the Michael J Fox Foundation, and the Parkinson Disease Foundation, not related to the submitted work. He consults for Caremark/CVS. S.K. has received funding from the National Institutes of Health: NINDS #K08 NS083738 (principal investigator), the Louis V. Gerstner Jr. Scholar Award, the Parkinson’s Disease Foundation, the American Parkinson’s Disease Association, the International Essential Tremor Foundation, NIEHS Pilot Grant ES009089 (principal investigator), and the Smart Foundation. K.S.M. reports grants from NIH [#NS036630 (PI), 1UL1 RR024156-01(Director PCIR), PO412196- G (Co-I), and PO412196-G (Co-I)], grants from steering committee for U01NS052592, grants from the Parkinson’s Disease Foundation, and grants from Michael J Fox Foundation, outside the submitted work. The remaining authors declare no conflict of interest.
References
-
- Zeigler, M. et al. A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced beta-glucocerebrosidase activity. J. Neurol. Sci. 339, 210–213 (2014). - PubMed
-
- Dardis, A. et al. Biochemical and molecular findings in a patient with myoclonic epilepsy due to a mistarget of the beta-glucosidase enzyme. Mol. Genet. Metab. 97, 309–311 (2009). - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
